When Barclays in 2012 became the first big bank to be fined for trying to rig the Libor interbank rate, its chief executive lost his job within days.
Here’s a figure that could have you reaching for an EpiPen, assuming you can afford one: one billion dollars.
Alphabet’s partnership with GlaxoSmithKline is by no means its first foray into the world of biotechnology.
John McDonnell would look to reform or scrap a £1bn tax relief that was initially designed by the previous Labour government as a means of promoting innovation in companies, including in the pharmaceutical industry.
Martin Shkreli, the reviled former drug company entrepreneur, may face yet more charges in a securities fraud investigation, his defense attorneys revealed at a hearing on Tuesday in New York city.
Barack Obama’s derailment of Pfizer’s $160bn (£114bn) merger with Allergan sparked immediate speculation on Wednesday that the US drugs company would turn its attention to another big pharmaceutical takeover.
The largest pharmaceuticals merger in history, between Pfizer and Allergan, could be abandoned after the US government took fresh steps to clamp down on tax avoidance deals.